Anthracyclines inhibit SARS-CoV-2 infection
Vaccines and drugs are two effective medical interventions to mitigate SARS-CoV-2 infection. Three SARS-CoV-2 inhibitors, remdesivir, paxlovid, and molnupiravir, have been approved for treating COVID-19 patients, but more are needed, because each drug has its limitation of usage and SARS-CoV-2 const...
Main Authors: | Zhen Wang, Qinghua Pan, Ling Ma, Jianyuan Zhao, Fiona McIntosh, Zhenlong Liu, Shilei Ding, Rongtuan Lin, Shan Cen, Andrés Finzi, Chen Liang |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-09-01
|
Series: | Virus Research |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0168170223001260 |
Similar Items
-
Anthracycline-induced hypertension in pediatric cancer survivors: unveiling the long-term cardiovascular risks
by: Andia Taghdiri
Published: (2024-06-01) -
Anthracycline-induced cardiotoxicity – primary preventive options. An overview
by: S. Slavcheva
Published: (2024-05-01) -
Echocardiographic Changes after Treatment with Anthracyclines in Children
by: Hamid Amoozgar, et al.
Published: (2012-03-01) -
Anthracycline-induced cardiotoxicity: mechanisms, monitoring, and prevention
by: Yun Qiu, et al.
Published: (2023-12-01) -
Survivorship clinic attendance improves completion but not timeliness of cardiac surveillance post anthracyclines
by: Zac Forbes, et al.
Published: (2025-02-01)